Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
- Submitting institution
-
University of Sussex
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 40578_63440
- Type
- D - Journal article
- DOI
-
10.1093/annonc/mdw316
- Title of journal
- Annals of Oncology
- Article number
- -
- First page
- 2046
- Volume
- 27
- Issue
- 11
- ISSN
- 0923-7534
- Open access status
- Compliant
- Month of publication
- August
- Year of publication
- 2016
- URL
-
http://dx.doi.org/10.1093/annonc/mdw316
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
19
- Research group(s)
-
-
- Citation count
- 15
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The author made a substantial contribution to the conception and design of the study and critiqued the output for important intellectual content.
- Non-English
- No
- English abstract
- -
